Philip Lienau

This inventor holds 80 USPTO granted patents and 49 published patent applications, plus 17 CIPO patents and 61 EPO patents, primarily in Cancer Treatment Compounds (CPC class C07D). Top assignees: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property Gmbh, Bayer Aktiengesellschaft. Active years: 2010-2026.

USPTO Granted Patents = 80 (Patent Applications = 49)

% Patents Active = 35.0

CIPO Patents = 17 (Patent Applications = 29)

EPO Patents = 61 (Patent Applications = 112)

Average Co-Inventor Count = 9.3

ph-index = 7

Forward Citations = 195(Granted Patents)

Forward Citations (Not Self Cited) = 134(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Potsdam, DE (2021)
Leverkusen, DE (2022)
Berlin, DE (2010 - 2024)

Company Filing History:

51 out of 380

Bayer Pharma Aktiengesellschaft

patents

26 out of 721

Bayer Intellectual Property Gmbh

patents

12 out of 12,223

Bayer Aktiengesellschaft

patents

4. 10 out of 480

The Broad Institute, Inc.

patents

5. 7 out of 1,264

Dana-Farber-Cancer Institute Inc.

patents

6. 1 out of 1

Bayer Pharma Aktiengesellscaft

patent

7. 1 out of 192

Bayer Schering Pharma Ag

patents

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

Cancer Treatment

PTEFb Inhibitors

Macrocyclic Compounds

Heteroarylbenzimidazole

Dihydrooxadiazinones

Aminoimidazopyridazines

Stratification Methods

Hyperproliferative Diseases

Indole Derivatives

Bub1 Kinase Inhibitors

Triazin Compounds

Fluorinated Derivatives

80 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12692261 - Substituted heterocyclic compounds and therapeutic uses thereof (2026-07-28),

2. 12565496 - SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF (2026-03-03),

3. 12427153 - 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases (2025-09-30),

4. 12258323 - Dihydrooxadiazinones (2025-03-25),

5. 12053476 - Compounds, compositions and methods for cancer patient stratification and cancer treatment (2024-08-06),

6. 11773070 - Dihydrooxadiazinones (2023-10-03),

7. 11691986 - PTEFB inhibiting macrocyclic compounds (2023-07-04),

8. 11529356 - 2-(morpholin-4-yl)-1,7-naphthyridines (2022-12-20),

9. 11492358 - Macrocyclic indole derivatives (2022-11-08),

10. 11427553 - Dihydrooxadiazinones (2022-08-30),

11. 11254690 - PTEFb inhibiting macrocyclic compounds (2022-02-22),

12. 11242356 - PTEFb inhibiting macrocyclic compounds (2022-02-08),

13. 11142522 - Compounds, compositions and methods for cancer treatment (2021-10-12),

14. 10981932 - Macrocyclic indole derivatives (2021-04-20),

15. 10966986 - Compounds, compositions and methods for cancer patient stratification and cancer treatment (2021-04-06),

Title: Philip Lienau: The Visionary Inventor Shaping Tomorrow's World

Introduction:

Philip Lienau, a brilliant inventor based in Berlin, DE, has dedicated his life to pioneering innovations that have the potential to transform our world. With an impressive portfolio of 75 patents, Lienau's impact on technology and healthcare is nothing short of extraordinary.

Latest Patents:

Two of Lienau's latest patents showcase the breadth of his ingenuity. The first is centered on Dihydrooxadiazinones, a group of compounds designed for the treatment and prevention of hyperproliferative diseases. The second patent pertains to PTEFB inhibiting macrocyclic compounds, offering a novel approach to tackling various disorders, including hyper-proliferative disorders, infectious diseases, and cardiovascular issues.

Career Highlights:

Having contributed significantly to Bayer Pharma Aktiengesellschaft and Bayer Intellectual Property GmbH, Lienau's career is marked by groundbreaking advancements in pharmaceuticals and biotechnology. His relentless pursuit of innovation has led to the development of transformative solutions that address some of the most pressing challenges in healthcare today.

Collaborations:

Throughout his illustrious career, Philip Lienau has collaborated closely with esteemed colleagues such as Gerhard Siemeister and Ulf Bömer. Together, they have pushed the boundaries of scientific discovery, fostering a culture of creativity and excellence that continues to yield remarkable results.

Conclusion:

In conclusion, Philip Lienau's unwavering commitment to innovation and his remarkable contributions to the field of technology and healthcare underscore his status as a true pioneer. His legacy will serve as a beacon of inspiration for generations of inventors to come, encouraging them to think boldly and strive for excellence in their pursuit of a better tomorrow.